alendronate has been researched along with Uveitis in 4 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance." | 8.93 | Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. ( Liu, L; Lu, Q; Ma, C; Tian, Y; Wang, R; Yin, F, 2016) |
| "To report a case of corneal graft rejection precipitated by severe uveitis secondary to alendronate therapy and to review the literature of relevance to this case." | 7.73 | Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. ( Richards, JC; Wiffen, SJ, 2006) |
| " Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance." | 4.93 | Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. ( Liu, L; Lu, Q; Ma, C; Tian, Y; Wang, R; Yin, F, 2016) |
| "To report a case of corneal graft rejection precipitated by severe uveitis secondary to alendronate therapy and to review the literature of relevance to this case." | 3.73 | Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. ( Richards, JC; Wiffen, SJ, 2006) |
| "Uveitis and scleritis are the most serious ocular side effects of bisphosphonate therapy." | 1.35 | Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. ( French, DD; Margo, CE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, Y | 1 |
| Wang, R | 1 |
| Liu, L | 1 |
| Ma, C | 1 |
| Lu, Q | 1 |
| Yin, F | 1 |
| French, DD | 1 |
| Margo, CE | 1 |
| Fraunfelder, FW | 1 |
| Winthrop, K | 1 |
| Suhler, E | 1 |
| Choi, D | 1 |
| Fraunfelder, FT | 1 |
| Richards, JC | 1 |
| Wiffen, SJ | 1 |
1 review available for alendronate and Uveitis
| Article | Year |
|---|---|
Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substituti | 2016 |
3 other studies available for alendronate and Uveitis
| Article | Year |
|---|---|
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databa | 2008 |
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphona | 2009 |
Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Graft Rejection; Humans; Keratoplasty, | 2006 |